Equities research analysts predict that ContraFect Corp (NASDAQ:CFRX) will report earnings of ($0.09) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for ContraFect’s earnings. The lowest EPS estimate is ($0.11) and the highest is ($0.07). ContraFect reported earnings of ($0.08) per share in the same quarter last year, which would indicate a negative year over year growth rate of 12.5%. The firm is expected to issue its next quarterly earnings results on Thursday, March 12th.
On average, analysts expect that ContraFect will report full-year earnings of ($0.10) per share for the current year, with EPS estimates ranging from ($0.14) to ($0.03). For the next year, analysts anticipate that the business will post earnings of ($0.39) per share, with EPS estimates ranging from ($0.51) to ($0.25). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for ContraFect.
ContraFect (NASDAQ:CFRX) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01.
Separately, Maxim Group reaffirmed a “buy” rating and issued a $2.00 target price on shares of ContraFect in a research report on Friday, October 4th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CFRX. Oracle Investment Management Inc. grew its position in ContraFect by 13.1% in the second quarter. Oracle Investment Management Inc. now owns 6,356,649 shares of the biotechnology company’s stock valued at $3,242,000 after acquiring an additional 735,450 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of ContraFect during the second quarter valued at approximately $343,000. Trellus Management Company LLC acquired a new position in shares of ContraFect during the second quarter worth $295,000. Hartwell J M Limited Partnership lifted its position in shares of ContraFect by 42.9% during the third quarter. Hartwell J M Limited Partnership now owns 200,000 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 60,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of ContraFect in the third quarter valued at $25,000. Hedge funds and other institutional investors own 31.23% of the company’s stock.
Shares of CFRX traded down $0.01 during midday trading on Friday, reaching $0.35. 200 shares of the company were exchanged, compared to its average volume of 266,063. ContraFect has a 1-year low of $0.27 and a 1-year high of $2.59. The stock has a 50-day moving average price of $0.32 and a 200-day moving average price of $0.40. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.79. The company has a market cap of $27.44 million, a price-to-earnings ratio of -0.94 and a beta of 0.23.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Featured Story: What does relative strength index mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.